Completed PHASE2 INTERVENTIONAL NCT00280917

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis

Sponsor: Can-Fite BioPharma

Conditions Rheumatoid Arthritis

Interventions CF101

Updated 7 times since 2017 Last updated: Aug 28, 2023 Started: Jun 30, 2006 Primary completion: Apr 30, 2007 Completion: Apr 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Rheumatoid Arthritis and is currently completed. Can-Fite BioPharma leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2023 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Can-Fite BioPharma

Data source: Can-Fite BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Albany, United States , Ashkelon, Israel , Beer Yaakov, Israel , Belgrade, Serbia , Bialystok, Poland , Brasov, Romania , Bucharest, Romania , Cleveland, United States , Cluj-Napoca, Romania and 17 more locations